Name of the Procedure:

Injection, ravulizumab-cwvz, 10 mg (HCPCS Code: C9052)

Summary

This procedure involves the administration of ravulizumab-cwvz, a medication given by injection to patients. It is typically performed to treat specific medical conditions requiring the drug's immunomodulatory effects.

Purpose

Ravulizumab-cwvz is used to treat certain types of autoimmune and blood disorders. It helps in managing conditions like paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The goal is to stabilize the patient's condition, reduce symptoms, and prevent further complications.

Indications

Ravulizumab-cwvz is indicated for:

• Patients diagnosed with paroxysmal nocturnal hemoglobinuria (PNH).
• Individuals with atypical hemolytic uremic syndrome (aHUS), a rare condition causing abnormal blood clotting.
• Patients who have not responded adequately to other treatments.

Preparation

• Prior to the injection, the patient should have a comprehensive medical exam.
• Blood tests and urine tests may be required to assess kidney function and overall health.
• Patients need to inform their healthcare provider about any medications they are currently taking.

Procedure Description

1. Preparation: The healthcare provider will prepare the required dose of ravulizumab-cwvz.
2. Administration: The medication is administered via intravenous (IV) infusion.
3. Monitoring: Throughout the procedure, vital signs are closely monitored to detect any adverse reactions.
4. Completion: The IV line is removed after the infusion, and the patient is observed for a short period for any immediate reactions.

Duration

The infusion typically takes about 2 hours to complete.

Setting

This procedure is usually performed in a hospital or an outpatient clinic setting where medical monitoring is available.

Personnel

• Registered Nurse (RN): Administers the medication and monitors the patient.
• Physician (MD): Oversees the procedure and manages any complications.
• Pharmacist: Prepares the medication for infusion.

Risks and Complications

• Common Risks: Headache, fatigue, nausea.
• Rare Risks: Severe allergic reactions, increased risk of infections due to immune system modulation.
• Complications Management: Immediate medical intervention in case of severe adverse reactions; pre-medication with antihistamines may be given to minimize allergic reactions.

Benefits

• Effective management of PNH and aHUS.
• Reduction in symptoms and prevention of disease progression.
• Improved quality of life for patients with these conditions.
• Benefits can typically be realized within weeks of starting treatment.

Recovery

• Post-infusion, patients are monitored for a short duration.
• Normal activities can usually be resumed shortly after the procedure.
• Follow-up appointments are crucial for monitoring the patient’s response to treatment and managing any side effects.

Alternatives

• Other immunomodulatory drugs or treatments may be an option.
• Bone marrow transplant for eligible patients with severe cases.
• Each alternative has its own risk and benefit profile which should be discussed with the healthcare provider.

Patient Experience

• During the procedure: Mild discomfort from the IV insertion may occur. Some patients might feel drowsy or relaxed.
• After the procedure: Most patients report feeling normal with minimal side effects. Pain management strategies include over-the-counter pain relievers if necessary.

Pain Management and Comfort Measures: Patients are encouraged to report any pain or discomfort so appropriate measures can be taken to ensure their comfort during and after the procedure.